healthcare innovation Archives

Conceptual illustration of robotic arms automating drug manufacturing, with a giant glass vessel pouring into bioreactors against the San Francisco skyline.

Multiply Labs Raises $75 Million as Physical AI Takes Aim at Biotech’s Manufacturing Bottleneck -( $AZN $KYTX $LEGN $NVS $TER )

by John F. Heerdink, Jr. October 11, 2026 614Views 0Likes

Backed by AstraZeneca and Teradyne, the robotics company is betting that the next breakthrough in medicine will need a breakthrough on the factory floor. Artificial intelligence can help design a promising medicine. It cannot deliver a dose by admiring its own calculations.…

Comic-style illustration titled “The Fund-Raisers!” showing investors, a biotech innovation globe, a Forbion shield and laboratories, with a speech bubble announcing “2.6 billion raised.”

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. October 8, 2026 645Views 0Likes

Two new funds, institutional backing and a pharmaceutical heavyweight give the European life sciences investor fresh capital to turn promising science into investable businesses. Biotechnology has never suffered from a shortage of ambitious ideas. Financing them is another matter. Forbion has just…

Alt Text: Illustration of the Nobel Prize in Medicine lighting a new bull market for brain science, featuring a glowing brain, neural connections, a rising stock-market chart and a charging digital bull above a city skyline as researchers look on.

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

by John F. Heerdink, Jr. October 5, 2026 339Views 0Likes

The 2026 Nobel Prize in Physiology or Medicine has put optogenetics, the science of using light to control precisely selected nerve cells, squarely in the global spotlight. For many, the award is more than a ceremonial victory lap for academic neuroscience:…

Promotional graphic for a Tribe Public CEO dinner event featuring Eupraxia Pharmaceuticals (NASDAQ: EPRX), James Helliwell, M.D., and the company’s 52-week EP-104GI clinical update for eosinophilic esophagitis. The image illustrates localized treatment at week zero, durable symptom control through week 52, and a stylized upward EPRX market graphic.

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

by John F. Heerdink, Jr. September 30, 2026 436Views 0Likes

Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX) has added a potentially important chapter to its eosinophilic esophagitis, or EoE, story: a single administration of its investigational localized therapy, EP-104GI, continued to show clinical-remission signals at 52 weeks in the highest-dose cohorts of the…

Investor-focused healthcare graphic showing a laboratory scene, a clinician holding a drug-delivery device, a glowing brain illustration, molecular imagery and a city skyline. The image highlights AbbVie Inc. (NYSE: ABBV) receiving FDA approval for JUVMO (tavapadon) for Parkinson’s disease and positions Serina Therapeutics Inc. (NYSE American: SER) and its SER-252 program as a potential next-generation therapy opportunity in advanced Parkinson’s disease.

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

by John F. Heerdink, Jr. September 29, 2026 478Views 0Likes

AbbVie Inc. (NYSE: ABBV) has secured (Sept. 28) FDA approval for JUVMO™ (tavapadon), a new once-daily Parkinson’s therapy, adding an important fresh option to a market long defined by the delicate art of managing motor symptoms, “OFF” time, dyskinesia and medication burden. For Serina…

Illustration of a futuristic biotech bear in a forest alongside a princess and armored knight, symbolizing the growing investment opportunity in durable drug-delivery therapies for retinal disease, eosinophilic esophagitis, and Parkinson’s disease.

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

by John F. Heerdink, Jr. September 28, 2026 500Views 0Likes

The biotech market has long rewarded breakthrough efficacy. Increasingly, it is also rewarding something patients and physicians understand with unusual clarity: less treatment burden. Fresh clinical updates from Kodiak Sciences Inc. (NASDAQ: KOD), Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX), and Serina Therapeutics Inc. (NYSE…

Dartboard with three darts clustered near the bullseye and “$150M” displayed at the center, symbolizing Beta Bionics’ targeted $150 million public offering.

Beta Bionics Raises $150 Million as FDA-Cleared Mint Patch Pump Sets Up 2027 Growth Story -( $BBNX )

by John F. Heerdink, Jr. September 17, 2026 307Views 0Likes

Beta Bionics, Inc. (NASDAQ: BBNX) has priced a $150 million public offering this week just as its product story is acquiring more commercial torque: FDA clearance for the Mint™ patch pump, a planned U.S. launch in the first quarter of 2027, and a…

Investor-themed graphic showing Tribe Public and ACOG logos above a rising green-and-gold stock chart, dollar signs, and the Zunveyl (benzgalantamine) 5 mg, 10 mg, and 15 mg branding against a modern city backdrop.

Alpha Cognition’s Commercial Alzheimer’s Story Is Getting Harder to Ignore -( $ACOG )

by John F. Heerdink, Jr. September 6, 2026 357Views 0Likes

Alpha Cognition Inc. (NASDAQ: ACOG) has moved meaningfully beyond the familiar small-cap biotech ritual of promising future potential. Since CEO Michael McFadden’s January 15, 2026 Tribe Public luncheon presentation during the J.P. Morgan Healthcare Conference week in San Francisco, the company has paired…

Investor infographic illustrating Eli Lilly and Company (NYSE: LLY) investing up to $2.875 billion to acquire Merida Biosciences, linking Lilly’s headquarters and cash investment to Merida’s antibody-engineering candidates, precision immunology research, and projected future revenue growth.

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

by John F. Heerdink, Jr. September 1, 2026 269Views 0Likes

Eli Lilly and Company (NYSE: LLY) is making a confident and distinctly forward-looking move beyond its blockbuster obesity and diabetes franchises. Its agreement to acquire privately held Merida Biosciences for up to $2.875 billion in cash is a bullish vote for precision immunology:…

Diverse group of physicians and healthcare professionals reviewing a laptop and tablet together in a hospital corridor, illustrating collaborative adoption of AI-powered clinical workflow tools.

Why Doctors’ AI Optimism Could Be a Quietly Powerful Tailwind for Doximity -( $DOCS )

by John F. Heerdink, Jr. August 25, 2026 279Views 0Likes

Doximity, Inc. (NYSE: DOCS) may be sitting at the intersection of two stubborn healthcare realities: physicians are exhausted by administrative overload, and the system cannot easily afford to lose more of them. Its emerging AI opportunity is compelling precisely because it is not…

Tag: healthcare innovation

Multiply Labs Raises $75 Million as Physical AI Takes Aim at Biotech’s Manufacturing Bottleneck -( $AZN $KYTX $LEGN $NVS $TER )

Forbion’s $2.6 Billion Biotech Raise Signals Smart Money Is Backing the Next Wave of Medicines -( $IBB $LLY $XBI )

Nobel Prize in Medicine Illuminates a New Bull Market for Brain Science -( $BIIB $DHR $GSGTF $ILMN $IRD $MLPT $NBIX $OCGN $REGN $TMO )

Eupraxia’s One-and-Done EoE Strategy Gains a 52-Week Tailwind -( $EPRX $IBB $REGN $SNY $XBI )

AbbVie’s JUVMO Approval Puts Parkinson’s Innovation Back in Motion And Serina Therapeutics Has a Timely Opening -( $ABBV $AMRX $SER $SUPN $IBB $XBI )

Biotech’s Durability Trade Is Getting Interesting: Kodiak, Eupraxia and Serina Put the Burden of Treatment in Focus -( $ABBV $EPRX $IBB $KOD $SER $XBI )

Beta Bionics Raises $150 Million as FDA-Cleared Mint Patch Pump Sets Up 2027 Growth Story -( $BBNX )

Alpha Cognition’s Commercial Alzheimer’s Story Is Getting Harder to Ignore -( $ACOG )

Eli Lilly’s $2.875 Billion Immunology Bet: Why Merida Could Be More Than a Pipeline Add-On -( $IBB $LLY $XBI )

Why Doctors’ AI Optimism Could Be a Quietly Powerful Tailwind for Doximity -( $DOCS )

Your Guide To Staying Informed In The Markets